The Evolving Landscape of Drugs for Rare Diseases in the Canadian Private Payer Market
How Canada's fragmented coverage system reaches — or fails to reach — patients with rare diseases.
Latest analysis
Thought Leadership
In-depth perspectives on the forces shaping Canadian market access.
Data Analytics
Short, data-driven reads from MORSE's Canadian market access intelligence.
Do DRDs Receive Aligned HTA Evaluations in Canada?
Canada's two major HTA agencies review drugs for rare diseases independently — how often do they reach the same conclusion?
Ontario's FAST Pilot: Early Data Shows Over 60% Faster Time to Listing
Eight months into the FAST pilot, oncology drugs are reaching Ontario public funding faster than the usual route.